Hypofractionation for Head and Neck Cancer - 2020 Annual Meeting
This course pulls together international experts in the use of hypofractionation for head and neck cancer, using a case based approach to illustrate common clinical scenarios. The impetus for this session is several-fold, including the high clinical relevance and well-recognized practice variability, coupled with the fact that the Annual Meeting theme is global health, and simultaneously a shift in the US towards an episode-based payment model, which incentivizes more efficient shorter course RT, when appropriate. As such we expect this panel will be very high yield for radiation oncologists, and will be quite lively. We have participants from the United States (Dr. Koyfman), the Christie Hospital in the United Kingdom (Dr. David Thomson), and Dr. Sandro Porceddu from University of Queensland in Australia. High yield and commonly encounters clinical scenarios will be addressed in a case-based format, which allows for audience input prior to consensus recommendations by our panelists. These cases are expected to include: (1) Palliative locally advanced case, especially for patients who are elderly, or travel from a distance, (2) an oligo-metastatic case, (3) recurrent unresectable disease in a previously radiated field, (4) hypo-fractionation regimens for skin cancer.
This activity is available from March 1 2021, through 11:59 p.m. Eastern time on February 29, 2024.
This activity was originally recorded at ASTRO’s virtual 2020 Annual Meeting, October 23-28th.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents.
Upon completion of this activity, learners should be able to:
- Identify patients who may be appropriate for treatment with hypofractionated radiotherapy to the head and neck, and define acceptable schemes based on a variety of scenarios.
- Implement hypofractionation schemes for head and neck cancer into routine clinical care; specifically, the ability to define normal tissue constraints that need to be respected in different settings.
- John Nicholas Lukens, MD is employed at Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania and has no financial relationships with a commercial interest.
- David Thomson, MD is employed at Department of Clinical Oncology, The Christie NHS Foundation Trust and has investment interest from Merck & Co., Inc. and Christie Private Care. Dr. Thomson receives research grants from Cancer Research UK.
- Shlomo Koyfman, MD is employed at Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic and has research grants from Merck. Dr. Koyfman has investment interests from BristolMyersSquibb and Varian Medical Systems.
- Sandro Porceddu, MBBS, PhD is employed at Princess Alexandra Hospital and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.